PD-L1 Gene Abnormality Detection for Cancer Treatment Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the effectiveness of PD-1/PD-L1 blockade treatments in malignant tumors are insufficient, particularly in identifying cases where the blockade is likely to be effective, due to limitations in evaluating PD-L1 expression through immunostaining.
Innovation Solution
A method involving comprehensive gene analysis, such as RNA sequencing and whole genome sequencing, to detect structural abnormalities in the PD-L1 gene, specifically focusing on deletions in the 3'UTR region, which correlates with increased PD-L1 mRNA and protein expression, thereby predicting the efficacy of PD-1/PD-L1 blockade treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If immunostaining is used to evaluate PD-L1 positive rate, then the treatment effectiveness can be predicted, but the sensitivity and specificity are insufficient
Solution Approach 1:
The invention changes the evaluation parameter from PD-L1 protein expression level (detected by immunostaining) to PD-L1 gene structural abnormality status (detected by gene analysis). This parameter change enables more accurate prediction of treatment effectiveness by identifying specific genomic alterations (such as 3'UTR deletions) that drive PD-L1 overexpression, thereby improving both sensitivity and specificity compared to conventional immunostaining methods
2Measurement precision
If comprehensive gene analysis is performed to detect PD-L1 structural abnormalities, then the prediction accuracy of treatment effectiveness is improved, but the examination complexity increases
Solution Approach 1:
The invention extracts and focuses on a specific, clinically relevant genomic feature (PD-L1 gene structural abnormalities, particularly 3'UTR region deletions) from the complex landscape of potential genetic variations. By targeting this specific abnormality type that is directly associated with PD-L1 overexpression and treatment response, the method achieves high prediction accuracy while avoiding the need for comprehensive analysis of all possible genetic variations, thus reducing examination complexity
Data Source
AI summary
An object of the present invention is to provide an effective method of predicting an effect of treatment by a PD-1/PD-L1 blockade, which is a method of predicting whether or not PD-1/PD-L1 blockade is effective for treatment of a subject suffering from a malignant tumor, which comprises detecting abnormality of genome relating to effectiveness of the PD-1/PD-L1 blockade in a tumor cell taken from the subject and evaluating the PD-1/PD-L1 blockade as useful for the treatment of the subject when there is the abnormality.